NCT06222944View on ClinicalTrials.gov

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 25, 2024

Primary Completion Date

August 25, 2025

Study Completion Date

August 25, 2026

Conditions
Gastric CancerAdenocarcinoma of Esophagogastric Junction
Interventions
DRUG

Anlotinib

Anlotinib: 12mg PO, QD, D1-14, Q3W;

DRUG

TQB2450

TQB2450: 1200 mg, IV, D1, Q3W

DRUG

Albumin-Bound Paclitaxel

125mg/m2 IV D1,8，Q3W

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Peking University

OTHER